Dan Wichman currently serves as Executive Advisor to Gurnet Point Capital. He has worked on the buyside investing in the healthcare sector for more than two decades, most recently for 11 years as the partner responsible for pharmaceutical and biotechnology investments at Broadfin Capital. At Broadfin, a fund focused on small and mid-capitalization healthcare companies, he helped grow the fund from less than $50 million to more than $1 billion in assets.
Prior to Broadfin, Dan worked for more than five years as senior pharmaceutical analyst at the Galleon Group, a large multi-strategy hedge fund. He is an experienced public markets investor who has invested extensively in both commercial and development stage companies. He has also participated in numerous public financings of healthcare companies over the past 20+ years.
He holds a BA in Public Policy from Duke University.
.svg)
Passion, accountability, and collaboration. At Paratek, we count on each other to build a company that saves lives. Learn more about life @Paratek.
Explore Careers.png)
